Company intelligence / Profile preview
Noxopharm Limited
Sydney–Castle Hill, NSW, Australianoxopharm.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Noxopharm’s lead clinical candidate SOF-SKN, an oligonucleotide TLR7/8 antagonist from the Sofra™ platform, will enter first-in-human trials for cutaneous lupus erythematosus in early calendar year 2025. The company previously advanced Veyonda® for oncology indications into Phase I/II trials but it remains unapproved. The pipeline includes preclinical programs leveraging proprietary platforms in both oncology and autoimmunity. Initial safety data from the HERACLES trial of SOF-SKN are expected within weeks of dosing; full analysis by late next year.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesOligonucleotides
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Pharmorage Pty Ltd—source of much preclinical technology; no major pharma partnerships disclosed as of latest updates
Beyond the preview
Go deeper on Noxopharm Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noxopharm Limited.